Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Aortic Regurgitation III: Medical Management

Aortic Regurgitation III: Medical Management

Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...

Mitral Valve Prolapse I: Introduction

Mitral Valve Prolapse I: Introduction

IntroductionThe mitral valve, one of the heart's four valves, regulates blood flow. These valves have flaps that open and close to direct blood properly through the heart and body. During each heartbeat, the flaps open for blood to pass through and seal shut to prevent backflow. Specifically, the mitral valve opens to allow blood flow from the heart's upper left chamber to the lower left chamber. It then closes securely as the lower left chamber contracts to pump blood to the body, preventing...

Mitral Valve Prolapse II: Assessment and Management

Mitral Valve Prolapse II: Assessment and Management

IntroductionA range of clinical features characterizes Mitral Valve Prolapse (MVP), but it is important to note that many individuals with MVP are asymptomatic and may remain so throughout their lives. For those who do exhibit symptoms, the following are the key clinical features:Palpitations: This is a common symptom where individuals feel an irregular or rapid heartbeat. Palpitations in MVP are often due to arrhythmias such as premature ventricular contractions or supraventricular tachycardia.

Mitral Regurgitation III: Medical Management

Mitral Regurgitation III: Medical Management

Mitral regurgitation (MR) is characterized by retrograde blood circulation from the left ventricle into the left atrium due to inadequate mitral valve closure. The severity of the condition, symptoms, and underlying cause determine treatment strategies.Monitoring and Pharmacological TreatmentPatients with mild to moderate MR typically do not need immediate intervention but regular monitoring to assess progression and guide treatment. Patients with mild MR should have an echocardiogram every 3-5...

Cardiomyopathy V: Interprofessional Care

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Once and thrice weekly interval training in adults with central obesity: a randomized controlled trial.

Nature communications·2026

Same author

Novel Approaches for the 3D Printing of Collagen-Sourced Biomaterials Against Infectious and Cardiovascular Diseases.

Gels (Basel, Switzerland)·2025

Same author

Effects of volume-matched once-weekly and thrice-weekly high-intensity interval training (HIIT) on body adiposity in adults with central obesity: Study protocol for a randomized controlled trial.

Journal of exercise science and fitness·2024

Same author

Telehealth of cardiac devices for CVD treatment.

Biotechnology and bioengineering·2023

Same author

Enzyme Responsive Delivery of Anti-Retroviral Peptide via Smart Hydrogel.

AAPS PharmSciTech·2022

Same author

Effects of one-year once-weekly high-intensity interval training on body adiposity and liver fat in adults with central obesity: Study protocol for a randomized controlled trial.

Journal of exercise science and fitness·2022

Search research articles

Related Experiment Video

Updated: May 24, 2026

Protocol for Relative Hydrodynamic Assessment of Tri-leaflet Polymer Valves

Protocol for Relative Hydrodynamic Assessment of Tri-leaflet Polymer Valves

Published on: October 17, 2013

Advanced polymeric matrix for valvular complications.

Gayathri Acharya¹, Richard A Hopkins, Chi H Lee

¹Division of Pharmaceutical Sciences, School of Pharmacy, University of Missouri-Kansas City, Kansas City, Missouri 64108, USA.

Journal of Biomedical Materials Research. Part A

|February 17, 2012

Summary

This summary is machine-generated.

This study developed Poly(L-lactic acid) (PLLA) systems with nanoparticles releasing nitric oxide (NO) to prevent heart valve calcification and inflammation. The PLLA-based system effectively reduced valvular complications without cytotoxicity.

More Related Videos

A Simplified Stepwise Approach to Echo Guidance during Percutaneous Mitral Valve Repair

A Simplified Stepwise Approach to Echo Guidance during Percutaneous Mitral Valve Repair

Published on: October 16, 2021

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock

Published on: June 12, 2021

Related Experiment Videos

Last Updated: May 24, 2026

Protocol for Relative Hydrodynamic Assessment of Tri-leaflet Polymer Valves

Protocol for Relative Hydrodynamic Assessment of Tri-leaflet Polymer Valves

Published on: October 17, 2013

A Simplified Stepwise Approach to Echo Guidance during Percutaneous Mitral Valve Repair

A Simplified Stepwise Approach to Echo Guidance during Percutaneous Mitral Valve Repair

Published on: October 16, 2021

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock

Published on: June 12, 2021

Area of Science:

Biomaterials Science
Cardiovascular Research
Nanotechnology

Background:

Heart valve complications, such as calcification and inflammation, pose significant clinical challenges.
Current treatments often have limitations, necessitating novel therapeutic strategies.
Sustained nitric oxide (NO) delivery shows potential for preventing valvular pathologies.

Purpose of the Study:

To develop Poly(L-lactic acid) (PLLA) matrix systems incorporating Poly(lactic-co-glycolic acid) (PLGA) nanoparticles (NPs) for sustained nitric oxide (NO) release.
To evaluate the efficacy of these PLLA-PLGA-NO systems in preventing valvular calcification and inflammation.
To assess the safety and underlying mechanisms of NO-mediated therapeutic effects.

Main Methods:

Preparation of PLLA matrices using the salt leaching method.
Incorporation of PLGA NPs containing nitric oxide donors (DETA NONOate) into PLLA matrices.
Characterization of matrix properties and drug release profiles.
Evaluation of cellular responses in porcine aortic valve interstitial cells (PAVICs), including calcium content, ALP activity, cGMP, ICAM-1 expression, and cell viability.

Main Results:

PLLA matrices embedded with PLGA-NPs effectively alleviated the calcification rate of VICs.
Significant increase in cGMP levels under osteoblastic conditions confirmed NO-cGMP signaling pathway mediation.
Reduced ICAM-1 expression indicated NO's inhibitory effect on tissue inflammation.
NO release prevented valvular calcification and inflammation without inducing cytotoxicity.

Conclusions:

The developed PLLA matrix system loaded with NO-donor-containing NPs offers a promising platform for sustained and controlled NO delivery.
This approach significantly reduces valvular complications, including calcification and inflammation.
The PLLA-PLGA-NO system demonstrates a favorable safety profile and therapeutic potential for heart valve disease management.